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Abstract 
 
It is now over a decade ago since it was first shown that chronic, but not acute, 
antidepressant drug treatment increases brain-derived neurotrophic factor (bdnf) 
mRNA levels in the rat hippocampus. These initial bdnf expression studies were soon 
followed by studies showing that the effects by antidepressant drugs on bdnf 
expression are more complex than originally stated. Thus, the selective serotonin re-
uptake inhibitors (SSRIs) produce a ‘biphasic effect’ on bdnf levels, involving a 
down-regulation at 4 hours (both acute and chronic treatment) and an increase at 24 
hours (only after chronic treatment). Surprisingly few studies have attempted to 
determine the role of 5-HT and its different receptors in the mediation of these effects. 
Therefore, the present study aimed to investigate the role of 5-HT receptor subtypes 
in mediating the two opposing effects of the SSRI fluoxetine on hippocampal bdnf 
expression. Our study shows that the transient fluoxetine-induced down-regulation of 
the bdnf gene expression depends on an intact 5-HT, but not noradrenaline, system or 
circulating glucocorticoids. Pre-treatment with the 5-HT4 antagonist SB 204070 
blocked the overall fluoxetine-induced inhibition of bdnf levels in hippocampus, 
while pre-treatment with the 5-HT2 antagonists ketanserin had an effect in the CA3 
but not in the dentate gyrus. However, the 5-HT1A antagonist WAY100,635 and the 5-
HT3 antagonist granisetron were both ineffective. In comparison, the previously 
reported acute (single administration) stimulatory action of the selective 5-HT6 
agonist LY-586713 on hippocampal bdnf expression, was still present following sub 
chronic (4 days), but not chronic (14 days), treatment. The effect on 5-HT6-mediated 
cell survival was also dependent on a similar length of treatment. Hence, our study 
found little support for a primary effect of 5-HT6 receptors in the mediation of chronic 
fluoxetine-induced up-regulation of bdnf expression or neurogenesis.   
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1. Introduction 
 
It is now over a decade ago since it was first shown that chronic antidepressant drug 
treatment increases brain-derived neurotrophic factor (BDNF) mRNA levels in rat 
brain regions, including the hippocampus. These initial bdnf expression studies 
formed the basis for the “neurotrophin hypothesis of depression”, which postulates 
that central BDNF deficiencies underlie depression, and that antidepressants work via 
the restoration of central BDNF activity (Duman et al., 1997; Neto et al., 2011). 
Clinical support for the neurotrophin hypothesis has been shown in studies 
demonstrating low hippocampal and serum BDNF levels in un-medicated depressed 
patients, and that these levels increase with antidepressant drug treatment (Chen et al., 
2001; Gorgulu and Caliyurt, 2009; Wolkowitz et al., 2011). Not all studies, however, 
fully support the neurotrophin hypothesis of depression (Groves, 2007) and recent 
findings point more towards BDNF involvement in the treatment than in the cause of 
depression (Martinowich et al., 2007). In addition, the effects of antidepressant drugs 
on bdnf expression through the blockade of serotonin transporter (i.e., SSRIs) are 
complex and depend on both treatment duration and the time after the last injection 
(Coppell et al., 2003; De Foubert et al., 2004; Khundakar and Zetterstrom, 2006). 
Thus, chronic administration (2 weeks’ treatment) of SSRIs, including fluoxetine, 
produced a ‘biphasic effect’ on bdnf levels, involving a down regulation at 4 hours 
and an up-regulation at 24 hours. While a single administration does not increase 
hippocampal bdnf at 24 hours, the inhibitory action at 4 hours is, however, still 
present (Coppell et al., 2003; Khundakar and Zetterstrom, 2006). Similarly, 
antidepressant drugs show a time-dependent biphasic modulation of human bdnf 
expression (Donnici et al., 2008). In spite of a plausible role for an interaction 
between BDNF and 5-HT in the treatment of depression, surprisingly little is known 
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regarding individual 5-HT receptor subtypes and their actions on bdnf expression. In 
this respect, we have recently shown that the inhibitory action by the SSRI paroxetine 
on bdnf expression appears to be mediated indirectly via GABAB receptor stimulation 
(Khundakar and Zetterstrom, 2011). However, the 5-HT receptor subtype that initiates 
this effect (by possibly increasing GABA release) is not known. In addition, we have 
previously shown that a single administration of the selective 5-HT6 receptor agonist 
LY 586713 enhances bdnf expression, making this receptor subtype a possible 
candidate for also mediating the increase in bdnf expression following chronic SSRI 
treatment (de Foubert et al., 2007). 
 
In the present study, we firstly sought to identify the 5-HT receptor subtype 
responsible for SSRI induced down-regulation of hippocampal bdnf levels previously 
detected at 4 hours after both acute and chronic treatment (Coppell et al., 2003) 
Secondly, we investigated if the previously reported acute stimulatory action of the 
selective 5-HT6 agonist LY-586713 on hippocampal bdnf expression prevails 
following sub-chronic (4 days) and chronic (14 days) treatment. Finally, we examined 
if 5-HT6 agonist administration resulted in hippocampal neurogenesis (i.e., cell 
proliferation and survival), an effect previously shown to be influenced by BDNF and 
required for the behavioral effects of antidepressants and (Sairanen et al., 2005; 
Santarelli et al., 2003). 
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2. Experimental procedures 
2.1 Animals 
All procedures were carried out in accordance with the UK Animal Scientific 
Procedure Act (1986). Normal male Sprague-Dawley rats (225–250 g, Charles River, 
UK) or adrenalectomized rats (225-250 g, Harlan-Olac, Bicester, UK) were housed 
four per cage and allowed at least 10 days of habituation in the animal facilities before 
the start of any experimental procedure. Animals were kept under a 12-hour light/dark 
cycle in a temperature-controlled environment, with free access to food and water. All 
efforts were made to minimize animal suffering, reduce the number of animals used 
and to utilize alternatives to in-vivo techniques, if available.  
 
2.2. Drug treatment protocols 
All drugs were dissolved in saline, with the exception for LY-586713, which was 
dissolved in 25% w/v hydroxypropyl ß-cyclodextrin (Sigma, UK) in saline.  For acute 
treatment (single injections) animals were administered with fluoxetine (10 mg/kg, 
i.p.), renzapride (1 mg/kg, i.p.) or saline (1ml/kg, i.p.) and killed by decapitation 4 
hours later. Separate groups of rats were pre-treated, 30 minutes before the second 
injection with the following selective 5-HT antagonist: The 5-HT1A receptor 
antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazineyl]ethyl]-N-(pyridinyl)-
cyclohexanecarboximide-3-hydrochloride (WAY-100,635; 0.3mg/kg, s.c.), the 5-HT2 
receptor antagonist ketanserin (5mg/kg, i.p.), the 5-HT3 receptor antagonist 
granisetron (1mg/kg i.p.) or the 5-HT4 receptor antagonist 8-amino-7-chloro (N-butyl-
4-piperidyl) methylbenzo-1,4-dioxan-5-carboxylate hydrochloride (SB-204070; 
1mg/kg s.c.), or saline (1ml/kg, i.p.) prior to the injection of fluoxetine or renzapride 
(pre-treatment only with SB 204070) and sacrificed 4 hours after the last injection.  
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Doses and injection routes of all drugs were chosen according to previous literature, 
which have demonstrated robust pharmacological activity using in vivo models 
following injections (Barnes and Sharp, 1999; Coppell et al., 2003; De Foubert et al., 
2004; de Foubert et al., 2007; Dumuis et al., 1989; Fletcher et al., 1996; Kennett et al., 
1997; Nakayama, 2002). For chronic (14 days of treatment) or sub-chronic (4 days of 
treatment, only LY-586713) groups of rats were treated twice (9am and 5pm) daily 
with fluoxetine (10 mg/kg, i.p.), once daily with LY-586713 (1 mg/kg, s.c.) or the 
respective vehicles (1 ml/kg, i.p.) at the corresponding injection routes. 
 
2.3. 5-HT and noradrenaline lesion protocols 
In order to prevent 5,7-dihydroxytryptamine (5,7-DHT) from being taken up by 
noradrenergic neurons, rats were pre-treated with desipramine (25mg/kg, i.p.) 30 min 
prior to intracerebro-ventricular (i.c.v.) injection of 5,7-DHT or vehicle. For 
administration of 5,7-DHT (i.c.v.) or vehicle, halothane-anaesthetized rats were 
placed in a stereotaxic frame. The skull was exposed and a hole was drilled with 
stereotaxic guidance. The cannula was then slowly lowered into the right ventricle 
(AP 0.3, L 1.4, V 4.1 from bregma). 5,7-DHT (200 g in 10 l of vehicle) or vehicle 
(1% ascorbate-saline) was then infused over 5 minutes using a microinfusion pump 
(CMA). After the application of skin sutures, rats remained anaesthetized in the 
stereotaxic frame for up to 30 minutes before being returned to their home cages and 
allowed to recover for at least 2 weeks until further experimentation. To lesion central 
noradrenergic systems, rats were administered N-(2-chloroethyl)-N-ethyl-2-
bromobenzylamine (DSP-4; 50mg/kg i.p). The corresponding sham-lesioned control 
rats received 0.9% saline. Rats were recovered for one week before further 
experimentation. The extent of 5-HT and noradrenaline depletion following 5,7-DHT 
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and DSP-4 respectively was evaluated by analysis of hippocampal monoamine tissue 
content in the hippocampus from sham and lesioned rats using high-performance 
liquid chromatography with electrochemical detection (HPLC-EC). The regions of 
hippocampus were dissected out from individual rats, weighed and sonicated in, ice-
cold 0.1M perchloric acid.  The resulting suspension was then centrifuged for 5 min at 
14 000 g at 4C and the supernatant was assayed for content of 5-HT and 
noradrenaline using HPLC-EC (Zetterstrom et al., 1983). 
   
2.4. In-situ hybridization procedure 
Brain sections (10 μm) were cut on a cryostat, thaw-mounted onto gelatin-subbed 
slides and pre-treated for in-situ hybridization, using a standard protocol described 
previously (Pei et al., 1997). An oligonucleotide DNA probe complimentary to all 
bdnf transcripts (exon IX) (Aid et al., 2007) (5’ GGT CTC GTA GAA ATA TTG 
CTT CAG TTG GCC TTT TGA 3’) was identified using a basic BLAST search 
(National Institute for Health website: www.ncbi.nlm.nih.gov) and customer 
synthesized (Eurogentec DNA Service Ltd, Southampton, UK).  
 The oligonucleotide was 3’-tail labelled with 35S-dATP with terminal 
deoxynucleotide transferase. The labelled oligonucleotide probe (specific activity 
>109 cpm/µg) was added to each section (1 x 106 cpm/section) in hybridisation buffer, 
as previously described (Zetterstrom et al., 1998). Incubation was conducted in 
humidity chambers (containing 50% formamide in 4 x SSC) at calculated incubation 
temperature of 29.3 oC for 14–16 hours. Slides were then washed in 1 x SSC buffer at 
52 oC for 3 x 20 minutes, followed by 2 x 60 minutes at room temperature. Sections 
were air-dried and exposed to autoradiography film (Biomax, Amersham, UK) for 5–
7 days at room temperature.  
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Controls included the use of oligonucleotides in sense orientation and displacement 
with unlabelled probes. Searches conducted with the GenBank database using the 
BLAST program revealed no significant homology of the nucleotide sequences with 
other previously characterized rat brain genes. 
 
2.5. BrdU labelling and immunohistochemistry protocols 
Groups (n=6) of rats previously administered for 4 days (sub-chronic) or 14 days 
(chronic) with daily LY-586713 injections (1 mg/kg, s.c.) were injected with 4 x 
BrdU (75mg/kg in PBS, i.p.) every 2 hours, 24 hours after the last LY-586713 
administration. For measurements of cell proliferation and cell survival, rats were 
killed 24 hours and 28 days after the last BrdU injection respectively. Rats were 
transcardially perfused with saline, followed by 4% ice-cold paraformaldehyde 
(PFA). Brains were removed, post-fixed in 4% PFA overnight, placed in 30% sucrose 
in PBS for 3 days, removed from sucrose and frozen at -70 oC. Coronal sections 
(40µm) through the hippocampus (-2.40 mm to -4.80 mm, relative to bregma, Paxinos 
and Watson, 1986), were cut on a cryostat and stored in a cryoprotectant solution at -
20 oC prior to use in the immunocytochemistry procedure. Following rinsing in 0.02 
M PBS, sections were incubated in 1% H2O2 in PBS for 10 min, followed by 3x10 
min PBS washes. 
 
2.6. Quantification of BrdU-labelling 
Counting methods for BrdU-positive cells were adapted from previous studies 
(Malberg et al., 2000; Xu et al., 2004). Every sixth hippocampal section (240 m 
apart) from each animal was processed for BrdU-labelling. This was done to ensure 
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that the same neuron was not counted in more than one section. Using a light 
microscope set at x 40 objective, BrdU-postive cells were counted, blind to the 
treatment group, by drawing each cell onto a paper drawing corresponding to the 
region of the dentate gyrus being analysed. Labelled cells included in the count were 
those that were in or touching the subgranular zone (SGZ) and granular layer of the 
dentate gyrus (GCL) and those within the dentate hilus, which was taken as the 
complete area between the opposite arms of the dentate gyrus SGZ/GCL (Fig 4). All 
cells were counted regardless of size or shape. The focus of the microscope was 
adjusted by hand to count BrdU-labelled cells in different focal planes. Taking into 
account that every sixth section was analysed, the total number of BrdU-labelled cells 
from each brain was multiplied by 6 to give the total number of BrdU-positive cells 
per dentate gyrus.  
 
2.7. Data collection and analysis 
The relative abundance of total bdnf was determined by densitometric quantification 
of autoradiograms with correction for non-specific signals.  Developed films were 
digitized and analysed using a computerized image-capture and analysis system 
(MCID-4, Imaging Research, St. Catherine’s, Ontario, Canada).  Optical density 
values were converted to nCi/g tissue using a standard curve generated with 14C 
standards, calibrated against 35S standards to correct for non-linearity.  Three sections 
from each brain were hybridized with probe and the mean of the values from these 
three sections used to quantify mRNA levels for the selected brain region from each 
animal.  Graphing was performed using Excel (Microsoft Corporation).  Statistical 
analysis of data was performed using SPSS for Windows v.10.0 (SPPS Inc., Chicago, 
USA).  Comparisons between two groups (vehicle control and drug-treated) were 
 10 
made using Student’s unpaired two-tailed t-test.  Multiple comparisons were 
determined using one-way ANOVA with post-hoc comparisons with Bonferroni post-
hoc analysis.  Significance was determined at p<0.05. 
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3. Results 
 
 
 
3.1 Effects of 5-HT lesioning on acute fluoxetine-induced reduction of bdnf levels  
 
Previous studies have shown that a single injection of a range of antidepressant drugs 
decrease hippocampal bdnf expression at 4 hours after the injection (Coppell et al., 
2003; Khundakar and Zetterstrom, 2006; Khundakar and Zetterstrom, 2011). Here, 
we aimed to determine the involvement of 5-HT in this effect and therefore tested the 
effect of fluoxetine in 5-HT-lesioned rats. Intracerebroventricular injection of 5,7-
DHT significantly (p<0.01) reduced hippocampal 5-HT levels by 85.3%; from 
368+74 ng/g wet tissue in vehicle-injected controls (n=4) to 54+15ng/g in 5,7-DHT 
(200µg i.c.v, n=4) injected rats. Two weeks after injection, the 5,7-DHT did not 
significantly change basal hippocampal bdnf levels compared to sham treated rats. 
Fluoxetine significantly reduced bdnf levels in the dentate gyrus (-46%) and the CA1 
(-26%), but not in CA3, in sham treated rats when compared to the corresponding 
saline injected sham controls. In contrast, in 5,7-DHT lesioned rats fluoxetine did not 
reduce bdnf levels, demonstrating the importance of an intact 5-HT system for this 
effect (Fig 1). 
 
3.2 Effects of noradrenaline lesioning on fluoxetine induced reduction of bdnf levels 
 
Intraperitoneal injection of DSP-4 at one week significantly (p<0.01) reduced 
hippocampal noradrenaline levels by 73% from 817+107 ng/g wet tissue (saline 
injected controls, n=6) to 223+91 ng/g in rats injected with DSP-4 (50 mg/kg, n=6). 
The DSP-4 lesion per se did not alter bdnf levels in hippocampus compared to the 
corresponding sham group. Fluoxetine significantly decreased levels of bdnf in the 
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dentate gyrus of both sham (-25%) and DSP-4 (-19%) leisoned rats, but failed to show 
significant reductions in CA1 and CA3 for both treatment groups (Table 1).  
 
3.3 Effects of circulating glucocorticoids on fluoxetine-induced reduction of bdnf 
levels 
 
The effect of fluoxetine-induced down-regulation on hippocampal bdnf was examined 
in adrenalectomized rats. Adrenalectomy did not affect basal hippocampal bdnf 
expression. Neither did it prevent fluoxetine-induced inhibition of bdnf levels at 4 
hours after a single injection. Thus, in adrenectomized rats (n=6), fluoxetine caused 
significant down regulation of bdnf in all three hippocampal subregions: dentate gyrus 
(-33%), CA1 (-18%) and in the CA3 (-17%) compared to the corresponding sham 
controls (n=6), (Table 2). 
 
3.4 5-HT receptor subtypes and fluoxetine-induced inhibition of bdnf expression 
 
In order to identify the role of different 5-HT receptor subtypes in the mediation of 
acute fluoxetine-induced down-regulation of hippocampal bdnf, rats were pre-treated 
with selective 5-HT antagonists 30 minutes before the injection of fluoxetine. When 
the selective 5-HT4 antagonist SB-204070 (1 mg/kg, s.c.) was administered prior to 
fluoxetine (10 mg/kg, i.p.), there was a significant overall effect of the combined drug 
treatments on bdnf levels in dentate gyrus [F(3,41)=13.585, P<0.001], CA1 
[F(3,41)=8.320, P<0.001] and CA3 [F(3,41)=6.549, P<0.001]. Post-hoc analysis 
demonstrated that fluoxetine at 4 hours decreased bdnf levels in all regions. This 
effect was completely blocked by pre-treatment with SB-204070, which had no effect 
when administered on its own (Fig 2a). Renzapride (1 mg/kg, i.p.), a full 5HT4 
agonist, reduced hippocampal bdnf expression. When SB-204070 (1 mg/kg, s.c.) was Commented [a3]: Not necessary in the results section – 
no inference 
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administered 30 minutes prior to renzapride, there was a significant overall effect of 
the combined drug treatments on bdnf levels in dentate gyrus [F(3,16)=41.387, 
P<0.001] and CA3 [F(3,16)=9.700, P<0.001] but not in CA1 [F(3,16)=1.483, 
P=0.257]. Post-hoc analysis demonstrated that renzapride decreased bdnf levels in 
dentate gyrus and CA3, but not in CA1, and these effects were completely blocked by 
pre-treatment with SB-204070 (fig 2b). 
When the 5-HT1A antagonist, WAY-100,635 (0.3mg/kg, s.c.) was administered prior 
to fluoxetine, there was a significant overall effect of the combined drug treatments 
on bdnf levels in dentate gyrus [F(3,17)=21.078, P<0.001], CA1 [F(3,17)=19.044, 
P<0.001] and CA3 [F(3,17)=23.650, P<0.001]. Post-hoc analysis demonstrated that 
fluoxetine decreased bdnf levels in all regions. This effect was unaltered by combined 
treatment with WAY-100,635, which had no effects on bdnf expression when 
administered on its own (Table 3). 
When the 5-HT2 antagonist ketanserin (5 mg/kg, i.p.) was administered prior to 
fluoxetine, there was a significant overall effect of the combined drug treatments on 
bdnf levels in dentate gyrus [F(3,33)=21.840, P<0.001], CA1 [F(3,33)=3.225, 
P<0.035] and CA3 [F(3,33)=7.505, P<0.001]. Post-hoc analysis demonstrated that 
fluoxetine decreased bdnf levels in dentate gyrus and CA3. Combined treatment with 
ketanserin did not alter the effect in dentate gyrus; whilst in the CA3 pre-treatment 
with the antagonist significantly attenuated the effect by fluoxetine. Ketanserin on its 
own had no effect on hippocampal bdnf expression (Table 3). 
When the selective 5-HT3 antagonist granisetron (1mg/kg, s.c.) was administered 
prior to fluoxetine there was a significant overall effect of the combined drug 
treatment on bdnf levels in dentate gyrus [F(3,18)=21.344, P<0.001] and CA3 
[F(3,18)=7.677, P<0.01] but not CA1 [F(3,18)=1.722, P=0.198]. In this treatment 
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group, post-hoc analysis revealed that fluoxetine decreased bdnf levels in dentate 
gyrus but not CA1 or CA3 (p=0.068). These effects were unaltered by combined 
treatment with granisetron, which had no effect on bdnf expression on its own (Table 
3).      
 
 
3.5 Effects of 5-HT lesioning on chronic fluoxetine-induced increase of bdnf levels 
 
As shown previously (Coppell et al., 2003; De Foubert et al., 2004; Khundakar and 
Zetterstrom, 2006; Nibuya et al., 1995; Russo-Neustadt et al., 2004), twice daily 
injections of fluoxetine for 14 days at 24 hours after the last injection significantly 
(p<0.001) increased bdnf levels in the dentate gyrus of the hippocampus (126+6.1, 
mean+s.e.m. values shown as % of controls, n=6) compared to the corresponding 
saline control group (100+2.8, n=6). In contrast, this effect failed to reach significance 
in the CA1 (109+3.4) and levels were even slightly reduced in the CA3 (93+3.1). In 
order to test the influence of 5-HT in mediating the fluoxetine-induced increase in the 
dentate gyrus, we investigated the effect in rats lesioned with 5,7-DHT 2 weeks 
before the start of the chronic fluoxetine treatment (i.e., twice daily injections for 14 
days). Basal levels of bdnf expression at the end of the chronic treatment (i.e., 28 days 
after the 5,7-DHT lesion) were significantly  (p<0.05) elevated in the dentate gyrus of 
lesioned rats (120+3.9%, n=6) compared to the corresponding sham controls 
(100+1.9%). In the CA1 and CA3, bdnf levels were, however, not different in 5,7-
DHT lesioned rats compared to controls (data not shown). In contrast to the effect in 
non-lesioned rats, in animals lesioned with 5,7-DHT, 2 weeks prior to the start of the 
chronic drug schedule, fluoxetine failed to significantly increase bdnf levels in dentate 
gyrus (109+7.9%, n=6), compared to the corresponding 5,7-DHT-lesioned saline 
controls (100+3.9%, n=6). 
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3.6 Effect of repeated administration with the selective 5-HT6 agonist LY-558713 on 
hippocampal bdnf levels 
We have previously shown that a single administration of the selective 5-HT6 agonist 
LY-586713 (1 mg/kg, s.c.) increases bdnf expression in regions of the hippocampus at 
24 hours (de Foubert et al., 2007). Here, we investigated the action of LY-586713 at 
the same dose after sub chronic (once daily for 4 days) and chronic (14 days) 
administration on bdnf expression. Four days of LY-586713 administration up-
regulated bdnf expression in hippocampus. This effect reached significance in the 
CA1 (p<0.01) and CA3 (p<0.05), but not in the DG, compared to vehicle controls. In 
contrast, chronic treatment for 14 days resulted in no significant change in bdnf 
expression in any of the hippocampal brain region analyzed (Figs 3a and 3b). 
 
3.7 Effect of repeated administration with the selective 5-HT6 agonist LY-558713 on 
cell proliferation and cell survival 
 The number of BrdU-positive cells was determined after twice-daily administration 
of LY-558713 for 4 and 14 days, with sacrifice 24 hours (cell proliferation) or 28 
days (cell survival) after the last BrdU administration. As shown previously (Malberg 
et al., 2000; Nakagawa et al., 2002; Xu et al., 2004), BrdU-positive cells were mainly 
detected within the subgranular zone (SGZ) and the hilus of the dentate gyrus 24 
hours after BrdU injections. At 28 days after the last BrdU injection, positive cells 
were also clearly visible in the granular cell layer (GCL) (Fig 4). The average total 
BrdU-positive cell counts for the whole dentate gyrus region measured from -2.40mm 
to -4.80, relative to Bregma (Paxinos and Watson, 1986), was approximately 2500 
cells for the 24 hour treatment groups and 1500 cells for the 28 day treatment group, 
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corresponding with cell counts that that have been recorded in other published studies 
(Malberg et al., 2000; Nakagawa et al., 2002; Xu et al., 2004). The number of BrdU-
labelled cells was always visible higher in the SGZ/GCL as compared to the hilus 
after all types of treatment. Neither, 4 or 14 days of LY-586713 had any significant 
effect on cell proliferation in the SGZ; while in the hilus, there was a small albeit 
significant reduction (-28+7.2 %, mean+S.E.M., n=6) at 4 days, but not at 14 days, 
compared to the corresponding vehicle treated control group. In comparison, 4 days 
of LY-586713 treatment significantly increased cell survival in both the SGZ/GCL 
(+26%) and the hilus (+36%) region of the dentate gyrus compared to the 
corresponding vehicle treated control group (Fig 5). In contrast this effect was not 
seen at 14 days (Fig 6).  
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4. Discussion 
The SSRI type antidepressant drugs including fluoxetine produce a ‘biphasic effect’ 
on bdnf levels, involving a down-regulation at 4 hours (both acute and chronic 
treatment) and an increase at 24 hours (only after chronic treatment), (Coppell et al., 
2003; Khundakar and Zetterstrom, 2006). The present study aimed to investigate the 
role 5-HT receptor subtypes in mediating these two opposing effects of SSRIs on 
hippocampal bdnf expression. Our study shows that the transient fluoxetine-induced 
down-regulation of bdnf expression depends on an intact 5-HT system and is blocked 
by the selective 5-HT4 antagonist SB 204070. In comparison, the previously reported 
acute (single administration) stimulatory action of the selective 5-HT6 agonist LY-
586713 on hippocampal bdnf expression was still present following sub chronic (4 
days) but not after chronic (14 days) treatment. The effect on 5-HT6 mediated cell 
survival was also dependent on similar length of treatment. 
 
In the present study, we confirm that after a few hours (i.e., 2-4 hours) of an acute 
administration fluoxetine decreases hippocampal levels of bdnf (Coppell et al., 2003; 
Dias et al., 2003; Khundakar and Zetterstrom, 2006; Miro et al., 2002), an effect also 
detected after 5-HT releasing drugs (Zetterstrom et al., 1999). The hippocampus 
receives serotonergic and noradrenergic innervation and microdialysis studies have 
shown that fluoxetine acutely increases hippocampal 5-HT and noradrenaline release 
(Gartside et al., 1995; Stanford, 1996). The present study therefore sought to 
investigate the role of 5-HT and noradrenaline in the fluoxetine-induced decrease of 
hippocampal bdnf. In 5,7-DHT-lesioned animals, with a reduction of hippocampal 5-
HT levels by >85%, the fluoxetine-induced bdnf reduction was abolished. In rats pre-
treated with the noradrenline-depleting agent DSP4, which caused a >70% reduction 
 18 
of hippocampal noradrenaline, fluoxetine administration still resulted in significantly 
reduced bdnf expression, indicating a pivotal role for 5-HT but not noradrenaline in 
mediating this effect.  
 
Glucocorticoids down regulate bdnf in the hippocampus (Barbany and Persson, 1992; 
Schaaf et al., 1999) and 5-HT activates the HPA axis (predominantly via 5-HT2C 
receptor subtypes) thereby increasing circulating glucocorticoid levels (Heisler et al., 
2007). In adrenalectomized rats, the fluoxetine-induced decrease of bdnf was of a 
similar magnitude compared to sham-operated rats, making the involvement of 
glucocorticoids in this effect unlikely (Table 2). Acute stress decreases hippocampal 
bdnf independently of adrenal steroids (Murakami et al., 2005). Hence, the influence 
of stress on fluoxetine-induced inhibition of bdnf in the present study cannot be fully 
excluded (Smith et al., 1995; Vaidya et al., 1999). 
  
Pre-treatment with the selective 5-HT4 antagonist, SB-204070 (Kennett et al., 1997) 
blocked the fluoxetine-induced reduction of hippocampal bdnf (Fig 2a). Consistent 
with this effect, the 5-HT4 agonist renzapride (Dumuis et al., 1989) reduced bdnf 
levels, an effect also blocked by SB-204070 (Fig 2b). In contrast, pre-treatment with 
the selective 5-HT antagonists, WAY-100,635 or granisetron selective for 5-HT1A and 
5-HT3, respectively (Barnes and Sharp, 1999; Fletcher et al., 1996; Maksay, 1996) 
failed to attenuate the inhibitory action by fluoxetine on bdnf. The 5-HT2 antagonist 
ketanserin, previously shown to attenuate stress-induced reductions of bdnf  (Vaidya 
et al., 1997), blocked the inhibitory action by fluoxetine in CA3 but not in the dentate 
gyrus in our study. In line with this, the 5-HT agonist DOI has been shown to dose-
dependently decrease hippocampal bdnf (Vaidya et al., 1997). 
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Electrophysiological studies indicate the presence of excitatory 5-HT receptors on 
GABA-ergic interneurons innervating the granule cells in the dentate gyrus (Freund 
and Buzsaki, 1996; Piguet and Galvan, 1994). Taking into account the location of 
such 5-HT receptors, including 5-HT4 types, combined with our recent finding that 
SSRI-induced reduction of hippocampal bdnf is blocked by pre-treatment with 
selective GABAB antagonists, suggests that the acute fluoxetine-induced inhibitory 
action on bdnf levels in the dentate gyrus is triggered by a functional interaction 
between 5-HT and GABA (Khundakar and Zetterstrom, 2011). In support of this, 
previous electrophysiological studies demonstrate that 5-HT, under some 
experimental conditions, acts via 5-HT4 receptors to excite GABA-ergic interneurons 
in the hilus of the dentate gyrus (Bijak and Misgeld, 1997). Thus, the activation of 
excitatory 5-HT receptors (5-HT4 and/or 5-HT2) receptors, via fluoxetine-induced 
increases of extracellular 5-HT, could facilitate spontaneous GABA release in vivo, 
resulting in neuronal inhibition of the granule cells leading to reduced bdnf expression 
(Marmigere et al., 2003; Zafra et al., 1991).  
 
Previous studies show that acute and chronic fluoxetine administration rapidly 
increases the phophorylation of the hippocampal BDNF receptor TrkB, suggesting an 
increase in BDNF release, which could lead an auto-inhibitory action on bdnf 
transcription (Sairanen et al., 2005). It is, however, unlikely that this effect is related 
to the fluoxetine-induced inhibition of bdnf in the present study; thus the transient 
action on TrkB phosphorylation has recently been reported to be independent of 5-HT 
transporter blockade, as well as BDNF signaling (Rantamaki et al., 2011). 
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As shown previously, twice-daily injections of fluoxetine for 14 days, at 24 hours 
after the last injection, significantly increased levels of bdnf in the dentate gyrus of the 
hippocampus, (Coppell et al., 2003; De Foubert et al., 2004; Khundakar and 
Zetterstrom, 2006; Nibuya et al., 1995). We thus next sought to determine the 
influence of 5-HT in producing this fluoxetine-induced up-regulation of bdnf levels in 
the dentate gyrus. Two weeks’ fluoxetine treatment failed to increase bdnf  levels in 
dentate gyrus of 5,7-DHT-lesioned rats compared to the corresponding lesioned saline 
controls. This suggests that fluoxetine relies on an intact 5-HT system to produce this 
effect. However, at four weeks after the lesion, levels of bdnf were significantly 
elevated (+ 20%) in lesioned rats compared to the corresponding sham controls and it 
remains unclear if chronic fluoxetine would be able to increase it further. An 
increased expression of hippocampal bdnf has also been detected following 5-HT 
depletion by pCPA (Zetterstrom et al., 1999). Enhanced BDNF produced in response 
to a toxic injury could promote the sprouting of surviving 5-HT neurons; indeed, 5-
HT neurons express the gene for the tyrosine BDNF receptor Trkb (Madhav et al., 
2001; Mamounas et al., 1995). Similarly, bdnf expression is enhanced following a 
lesion of the dopamine system with 6-hydroxydopamine (Zhou et al., 1996).  
 
Preclinical data suggest a possible role for 5-HT6 receptors in depression; however, 
both blockade and stimulation of this receptor evoke an antidepressant effect (Borsini 
et al., 2011). In support of previous biochemical and behavioral evidence for 
antidepressant effects of acute 5-HT6 receptor stimulation (Nikiforuk et al., 2011; 
Svenningsson et al., 2007), we have previously shown that a single injection of the 
5HT6 agonist LY-586713 increases hippocampal bdnf, an effect completely blocked 
by the selective 5HT6 antagonist, SB-271046 and of similar magnitude to those shown 
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after chronic, but not acute treatment, with fluoxetine (de Foubert et al., 2007). Here, 
we show that repeated injection of the 5-HT6 agonist results in a time-dependent 
decline of its stimulatory action on hippocampal bdnf. Daily injections for 4 days of 
LY-586713, at 18 hour after the last injection, increased bdnf in CA1 and CA3 but not 
in the dentate gyrus (a non-significant trend only); however, after 14 days of 
treatment the drug failed to enhance hippocampal bdnf (Fig 3). The mechanism 
behind the time-dependent desensitized response by LY-586713 on hippocampal bdnf 
in the present study is not clear. It is, however, plausible that the acute stimulatory 
effect by the 5-HT6 agonist on bdnf is mediated via increased cyclic AMP levels and 
the subsequent activation of CREB a known transcription factor for bdnf, and that 
repeated administration of LY-586713 leads to a desensitization of this effect. Indeed, 
a previous study demonstrates rapid agonist-induced desensitization of 5-HT6 
receptor-induced stimulation of adenylyl-cyclase in 5-HT6 stably transfected HEK-
293 cells (Max et al, 1995). 
  
The present study shows that daily administration of LY-586713 for 4 days 
significantly increased cell survival, but not cell proliferation, in dentate gyrus to a 
similar magnitude previously recorded after 2-3 weeks of antidepressant treatment 
(Malberg et al., 2000; Sairanen et al., 2005). In contrast, 14 days of LY-586713 
treatment had no significant action on cell survival (Figs 4-6), reflecting its effect on 
bdnf. Taken together, these two separate findings relating to LY-586713 support the 
suggestion of desensitization of hippocampal 5HT6 receptors following chronic 
agonist stimulation. Assuming that LY-586713-induced enhancement of bdnf 
expression leads to increased levels of the corresponding protein, it is interesting to 
note that a recent study shows that BDNF down regulates 5-HT2A receptor protein 
Commented [a4]: Which agonist? Write it in place of this 
text 
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levels in hippocampal cultures. Interestingly, this effect was also shown to be time-
dependent and not present until at least 7 days of BDNF exposure (Trajkovska et al., 
2009). Thus, it can be speculated that increased BDNF levels following acute-sub 
chronic LY-586713 administration results in decreased 5-HT6 protein levels. 
 
In conclusion, the present study shows that the transient fluoxetine-induced down-
regulation of bdnf expression depends on an intact 5-HT system and is primarily 
mediated via 5HT4 receptors. In comparison, the study found little support for a 
primary role of 5-HT6 receptors in the mediation of chronic fluoxetine-induced up-
regulation of bdnf expression and cell survival.  
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Figure Legends 
 
Fig 1. Effect of 5-HT lesioning by 5,7-DHT on fluoxetine (F, 10 mg/kg, i.p.)-induced 
inhibition of bdnf levels in dentate gyrus (white bars), CA1 (grey bars) and CA3 
(black bars) of dorsal hippocampus at 4 hours after injection. Data are expressed as % 
of sham saline (S) controls and each column represents mean ± S.E.M. value from 5-6 
rats.  *P <0.05,  ***P <0.001 compared to Sham (S) controls and +P <0.05, ++P <0.01 
compared to Sham (F), one-way ANOVA, with Bonferroni post-hoc analysis. 
 
Fig 2. Effect of a 30 minutes’ pre-treatment period with the 5-HT4 receptor antagonist 
SB-204070 (SB, 1 mg/kg, i.p.) on a) fluoxetine- (Flu, 10 mg/kg, i.p.) and b) 
renzapride (Renz, 1 mg/kg, i.p.)-induced inhibition of bdnf levels in dentate gyrus 
(white bars), CA1 (grey bars) and CA3 (black bars) areas of dorsal hippocampus at 4 
hours after the last drug administration. Data are expressed as % of saline (Sal)/saline 
treated controls and each column represents mean ± S.E.M. value from 5-6 rats.  *P 
<0.05 and **P <0.01, compared to saline/saline controls and +P <0.05 and ++P <0.05 
compared to the corresponding saline/fluoxetine (a) or saline/renzapride (b) groups 
(one-way ANOVA, with Bonferroni post-hoc analysis). 
 
Fig 3. Effect of 4 days’ treatment (a) and two weeks (b) with the 5-HT6 receptor 
agonists LY-586713 (1 mg/kg, s.c., daily injections) on bdnf levels in dentate gyrus 
(DG), CA1 and CA3 of dorsal hippocampus at 4 hours after the agonist 
administration. Data are expressed as % of saline treated controls and each column 
represents mean ± S.E.M. value from 5-6 rats.  **P <0.01 compared to saline control 
(one-way ANOVA, with Bonferroni post-hoc analysis). 
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Fig 4. Representative photographic image of BrdU-labelling in the dentate gyrus (x 
10 magnification) 28 days following daily administration of vehicle (a) and the 5-HT6 
agonist LY-586713, 1mg/kg, s.c. (b). Arrow indicates BrdU-labelled cells in the in the 
subgranular zone and granular cell layer SGZ/GCL.  
 
Fig 5. Effect of daily injections of the 5-HT6 receptor agonists LY-586713 (1 mg/kg, 
s.c.) for 4 days on total number of BrdU-positive cells 28 days after the last BrdU 
injection (measure of cell survival) in the subgranular zone and granular cell layer 
SGZ/GCL and the hilus of the denate gyrus. Each column represents mean ± S.E.M. 
value from 5-6 rats.  *P <0.05 compared to saline control (Student’s un-paired t-test). 
 
Fig 6. Effect of daily injections with the 5-HT6 receptor agonists LY-586713 (1 
mg/kg, s.c.) for 4 days or 14 days on total number of BrdU-positive cells 28 days after 
the last BrdU injection (measure of cell survival) in the dentate gyrus (total cell count 
for: SGZ/GCL and the hilus). Each column represents mean ± S.E.M. value from 5-6 
rats.  *P <0.05 compared to the corresponding vehicle control groups (Student’s un-
paired t-test). 
 
Table 1. Effect of noradrenaline lesioning by DSP-4 on fluoxetine (F, 10 mg/kg, i.p.) 
- induced inhibition of bdnf levels in dentate gyrus, CA1 and CA3 of dorsal 
hippocampus at 4 hours after the fluoxetine injection. Data are expressed as % of 
sham saline (S) controls and each column represents mean ± S.E.M. value from 5-6 
rats.  *P <0.05, **P <0.01 compared to Sham (S) controls, one-way ANOVA, with 
Bonferroni post-hoc analysis. 
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Table 2. Effect of fluoxetine (Flu, 10 mg/kg, s.c.) at 4 hours after the injection on 
bdnf levels in: dentate gyrus, CA1 and CA3 of dorsal hippocampus in 
adrenoectomized (ADX) rats. Data are expressed as either percentage of sham ADX 
or saline (Sal) (ADX) and each column represent, mean ± S.E.M. value from 5-6 rats.  
*P <0.05 and **P <0.05 compared to the corresponding Sal (ADX) control group, 
(one-way ANOVA, with Bonferroni post-hoc analysis). 
 
Table 3. Effect of 30 minutes’ pre-treatment with 5-HT receptor subtype selective 
antagonists: WAY-100,635 (0.3 mg/kg, s.c.), ketanserin (Ket, 5 mg/kg, i.p.), 
granisetron (Gran, 1 mg/kg, i.p.) on acute fluoxetine (Flu) induced reduction of 
hippocampal bdnf  levels at 4 hours after the 2nd injection. Data are expressed as % of 
saline (Sal)/Sal treated controls and each column represents mean ± S.E.M. value 
from 5-6 rats.  *P <0.05 and **P <0.01, compared to saline/saline controls and +P 
<0.05, compared to the corresponding Sal/Flu group (one-way ANOVA, with 
Bonferroni post-hoc analysis. 
  
 
 
